Evidence map›Paper›PMID 36708680›Full record

ArticleEuropean journal of medicinal chemistry2023

Elevated labile iron in castration-resistant prostate cancer is targetable with ferrous iron-activatable antiandrogen therapy.

Ryan L Gonciarz, Sasank Sakhamuri, Nima Hooshdaran, Garima Kumar, Hyunjung Kim, Michael J Evans, Adam R Renslo

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of medicinal chemistry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. A tandem activity-based sensing and labeling strategy reveals antioxidant response element regulation of labile iron pools.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Ryan L GonciarzDepartment of Pharmaceutical Chemistry, University of California, San Francisco, CA, 94158, United States.
Sasank SakhamuriDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, CA, 94158, United States.
Nima HooshdaranDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, CA, 94158, United States.
Garima KumarDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, CA, 94158, United States.
Hyunjung KimDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, CA, 94158, United States.
Michael J EvansDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, CA, 94158, United States; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, 94158, United States. Electronic address: michael.evans@ucsf.edu.
Adam R RensloDepartment of Pharmaceutical Chemistry, University of California, San Francisco, CA, 94158, United States; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, 94158, United States. Electronic address: adam.renslo@ucsf.edu.
University of California, San Francisco · US

Funding

Chemical Methods for Ferrous Iron Dependent Drug DeliveryR01AI105106 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI RENSLO, ADAM R · 2013 to 2022
$4.6M
Understanding Efficacy and Fe(II)-Promoted Activation of 1,2,4-Trioxolanes in CancerR01CA260860 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI COLLISSON, ERIC, RENSLO, ADAM R · 2021 to 2025
$3.1M
Developing a pretargeting strategy to detect Fe(II) for nuclear medicine applicationsR01EB029429 · NIBIB · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI EVANS, MICHAEL JOHN, RENSLO, ADAM R · 2021 to 2024
$2.6M
NCI NIH HHS R01 CA260860NIAID NIH HHS R01 AI105106NIBIB NIH HHS R01 EB029429
6 · The paper itself

Abstract

Clinical responses to second generation androgen signaling inhibitors (e.g., enzalutamide) in metastatic castration-resistant prostate cancer (mCRPC) are variable and transient, and are associated with dose limiting toxicities, including rare but severe CNS effects. We hypothesized that changes to iron metabolism coincident with more advanced disease might be leveraged for tumor-selective delivery of antiandrogen therapy. Using the recently described chemical probes SiRhoNox and

Indexed as

Androgen AntagonistsProstatic Neoplasms, Castration-ResistantAnimalsHumansIronMaleMiceNitrilesTreatment OutcomeAndrogen AntagonistsIronNitriles

Identifiers

PMID36708680
PMCPMC10210592
OpenAlexW4315928968

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.